

Filed on behalf of Argentum Pharmaceuticals LLC

By:

Kevin B. Laurence
Laurence & Phillips IP Law LLP
1940 Duke Street, Suite 200
Alexandria, Virginia 22314
Tel: 703.448.8787
Fax: 703.439.1624
klaurence@lpiplaw.com

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC,
Petitioner

v.

COSMO TECHNOLOGIES LIMITED,
Patent Owner

Inter Partes Review No. IPR2018-00080
U.S. Patent No. 9,320,716 B2

PETITIONER'S EXHIBIT LIST

Pursuant to 37 C.F.R. § 42.63(e), Petitioner submits this Exhibit List.

Filed Exhibit	Description
1001	U.S. Patent No. 9,320,716 to Villa et al., "Controlled Release and Taste Masking Oral Pharmaceutical Compositions"
1002	U.S. Patent No. 8,784,888 to Villa et al., "Controlled Release and Taste Masking Oral Pharmaceutical Composition"
1003	Reserved
1004	Reserved
1005	Reserved
1006	Declaration of Hartmut Derendorf, Ph.D.
1007	Curricula Vitae of Hartmut Derendorf, Ph.D.
1008	U.S. Patent No. 5,681,584 to Savastano et al., "Controlled Release Drug Delivery Device"
1009	U.S. Patent No. 5,811,388 to Friend et al., "Delivery of Drugs to the Lower GI Tract"
1010	U.S. Patent No. 6,239,120 to Hallgren et al., "Method and Means for Treating Glomerulonephritis"
1011	U.S. Patent Appl. Pub. No. 2006/0134208 to Villa et al., "Controlled Release and Taste Masking Oral Pharmaceutical Composition"
1012	Markman Opinion and Order in <i>Cosmo Technologies Limited v. Alvogen Pine Brook, LLC.</i> , C.A. No. 15-193-LPS, ECF Nos. 167, 168 (D. Del. Sept. 7, 2016).
1013	Amendment and Response to Advisory Action filed on February 21, 2014 in U.S. Patent Appl. No. 13/617,138
1014	Substitute Specification (Clean Copy) filed on April 29, 2013 in U.S. Patent Appl. No. 13/617,138
1015	Amendment After Final filed on April 29, 2013 in U.S. Patent Appl. No. 13/617,138

Filed Exhibit	Description
1016	Amendment and Response to Office Action filed on July 1, 2013 in U.S. Patent Appl. No. 13/617,138
1017	U.S. Patent No. 6,607,751 to Odidi et al., "Controlled Release Delivery Device for Pharmaceutical Agents Incorporating Microbial Polysaccharide Gum"
1018	Campieri et al., <i>Oral Budesonide is as Effective as Oral Prednisolone in Active Crohn's Disease</i> , Gut, 41:209-214 (1997)
1019	Reserved
1020	Reserved
1021	Reserved
1022	PCT International Publication No. WO 96/36318, "Three-Phase Pharmaceutical Form With Constant and Controlled Release of Amorphous Active Ingredient for Single Daily Application"
1023	U.S. Patent No. 5,342,625 to Hauer et al., "Pharmaceutical Compositions Comprising Cyclosporins"
1024	PCT International Publication No. WO 99/39700, "Pharmaceutical compositions in form of nanoparticles comprising lipidic substances and amphiphilic substances and related preparation process"
1025	FDA Inactive Ingredient Guide 1996/1997
1026	Handbook of Pharmaceutical Excipients (Wade and Weller, eds., 2d ed. 1994)
1027	Reserved
1028	Remington: The Science and Practice of Pharmacy, Vol. 1 (1995)
1029	Reserved
1030	Hawley's Condensed Chemical Dictionary (John Wiley & Sons, Inc., 13th ed. 1997)
1031	Reserved
1032	Entocort® EC Highlights of Prescribing Information

Filed Exhibit	Description
1033	Svensson et al., <i>Hydration of an Amphiphilic Excipient</i> , Gelucire 44/14, 2004, <hal-00015990>
1034	U.S. Patent No. 6,395,300 to Straub et al., “Porous Drug Matrices and Methods of Manufacture Thereof”
1035	Flanders et al., <i>The Control of Drug Release From Conventional Melt Granulation Matrices</i> , Drug Development & Industrial Pharmacy, 13(6):1001-1022 (1987)
1036	Gandhi et al., <i>Extrusion and Spheronization in the Development of Oral Controlled-Release Dosage Forms</i> , Pharmaceutical Sci. & Tech. Today 2(4):160 (1999)
1037	US Patent Formulation”
1038	Daly et al., <i>The Effect of Anionic Surfactants on the Release of Chlorpheniramine from a Polymer Matrix Tablet</i> , Int’l J. of Pharmaceutics, 18:201-05 (1984)
1039	S.S. Davis, <i>The Design and Evaluation of Controlled Release Dosage Forms for Oral Delivery</i> , S.T.P. Pharma 3(5):412-417 (1987)
1040	International Publication No. WO 2005/075002 to Taguchi et al.
1041	English Translation of International Publication No. WO 2005/075002 to Taguchi et al. and corresponding Translation Certification
1042	International Publication No. WO 2005/007835 to Wang
1043	Ohno-Matsui, <i>In vitro and in vivo characterization of iris pigment epithelial cells cultured on amniotic membranes</i> , Molecular Vision, Vol. 12, pp. 1022-1032 (August 2006)
1044	Hanada et al., <i>Multilayered Amniotic Membrane Transplantation for Severe Ulceration of the Cornea and Sclera</i> , American J. of Ophthalmol., Vol. 131, No. 3, pp. 324-331 (March 2001)
1045	Qiu et al., <i>Design of sustained-release matrix systems for a highly water-soluble compound, ABT-089</i> , Int’l J. of Pharmaceutics 157:43-52 (1997)
1046	M. Efentakis et al., <i>The Influence of Surfactants on Drug Release from a Hydrophobic Matrix</i> , Int’l J. Pharm. 70:153-58 (1991)

Filed Exhibit	Description
1047	Uceris® website, https://www.uceris.com/tablet/ (accessed on March 5, 2017)
1048	Santarus' CEO Discusses FDA Approval Of UCERIS (Budesonide) For The Induction Of Remission In Patients With Active, Mild To Moderate Ulcerative Colitis (Transcript) (Jan. 15, 2013)
1049	Uceris® Instant Savings Program
1050	Transcript of the Second Quarter 2014 Earnings Conference Call of Salix Pharmaceuticals, Ltd.
1051	L.W. Doner, <i>Determining Sugar Composition of Food Gum Polysaccharides by HPTLC</i> , <i>Chromatographia</i> 2001, 53, May (No. 9/10)
1052	Amendment filed on January 15, 2013 in U.S. Patent Appl. No. 13/617,138
1053	Specification of U.S. Patent Application No. 10/009,532
1054	Specification of 12/210,969 application
1055	Specification of 13/249,839 application
1056	Specification of 13/462,409 application
1057	Final Office Action of March 6, 2013 in U.S. Patent Appl. No. 13/617,138
1058	Applicant-Initiated Interview Summary of April 23, 2013 in U.S. Patent Appl. No. 13/617,138
1059	Original Specification as filed on September 14, 2012 in U.S. Patent Appl. No. 13/617,138
1060	Orange Book Listing of Uceris® (accessed on March 8, 2017)
1061	Hawley's Condensed Chemical Dictionary (John Wiley & Sons, Inc., 13th ed. 1997)
1062	N. Robinson, <i>Surface Interaction of Lecithin and Lysolecithin</i> , <i>J. of Pharmacy and Pharmacology</i> , 12(1) 609-616 (1960)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.